News Daily News Universal Risk Tool Works Well in Both Primary and Secondary Prevention Michael O'Riordan February 01, 2024
News Daily News GLP-1 Receptor Agonists Come With Broad Array of Benefits, Risks Todd Neale January 21, 2024
News Daily News Top General Cardiology and CVD Prevention News of 2023 Yael L. Maxwell January 03, 2024
News Daily News Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk Todd Neale December 12, 2023
News Daily News Long-term ALLHAT Data Affirm Parity of Antihypertensive Meds Todd Neale December 06, 2023
News Daily News ‘Smoldering Epidemic’ of CVD Risk Factors in Middle-Aged Adults Michael O'Riordan November 21, 2023
Presentation AHA 2023 Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial Presenter: Jamie Kitt November 17, 2023
Presentation AHA 2023 Hypertension Treatment in Nigeria: Early Results of a Type 2 Hybrid Effectiveness and Implementation Interrupted Time Series Trial Presenter: Dike Ojji November 17, 2023
News Daily News Mortality Risk Varies Among Patients With Very High LDL Levels Michael O'Riordan November 17, 2023
Presentation AHA 2023 Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events Presenter: Jing Li November 16, 2023
News Conference News AHA 2023 ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients Todd Neale November 13, 2023
News Conference News AHA 2023 POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy L.A. McKeown November 13, 2023
News Conference News AHA 2023 Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics Todd Neale November 11, 2023
News Daily News FDA Grants Tirzepatide a New Indication for Obesity Management L.A. McKeown November 08, 2023
News Daily News Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study L.A. McKeown October 10, 2023